Many traumatic brain injuries result in significant communication impairment across a spectrum that can range from limited speaking to apparent disorders of consciousness such as comas.
|Articles|September 16, 2022
Mental Health for Mental Health Professionals
Author(s)Psychiatric Times Editors
Tell us how you stay healthy and beat burnout for a chance to be featured in our Wellbeing Checkup video series.
Advertisement
Do you have a go-to method—or 2—for maintaining your mental and physical health? Psychiatric TimesTM wants to hear from you!
Contact us now to be featured in an upcoming episode of
If you would like to discuss your healthy habits in an upcoming episode of Wellbeing Checkup, write us at
Advertisement
Related to this article
Review the timeline for Igalmi in at-home treatment of agitation in bipolar disorder and schizophrenia.
Meta-analysis finds bright light therapy boosts remission and response in nonseasonal depression, offering a low-cost add-on to standard care.
Minerva Neurosciences webinar reported that roluperidone monotherapy improved primary negative symptoms and functioning in stable patients with schizophrenia who had a low relapse risk.
Teacher-recorded classroom engagement scores beat GPA at identifying middle schoolers who reported alcohol or cannabis use by eighth grade.
The FDA seems to have shelved the fast-track drug review initiative launched during the Trump administration.
Oveporexton (Orzeyful) is now available in the US by prescription for the treatment of narcolepsy type 1.
Explore the types of scams encountered in psychiatric practice in order to help identify those at risk.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Major Depressive Disorder With Mixed Features: Diagnosis and Treatment
2
FDA Shelves Fast-Track Drug Review Initiative
3
New National Guidance for Managing Medetomidine Intoxication and Withdrawal
4
Oveporexton Now Available: First and Only Orexin Agonist for Narcolepsy Type 1
5